Deal-Making Darling Among Latest To Retract China NDAs
This article was originally published in PharmAsia News
Very few people doubt about what China FDA can do to reduce its notorious drug approval backlog, the agency's actual moves and impact to the industry, however, is shocking to many. Meanwhile, a rigorous clinical data review has been expanded to Beijing and Shanghai with local FDA involved.
You may also be interested in...
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.